Matches in SemOpenAlex for { <https://semopenalex.org/work/W2412530943> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2412530943 endingPage "7" @default.
- W2412530943 startingPage "451" @default.
- W2412530943 abstract "Recurrent infection with HCV after liver transplantation is almost universal and is associated with substantial morbidity, mortality and graft loss. In contrast to immunocompetent individuals, HCV infection in immunosuppressed transplant recipients usually has an accelerated course. Acute hepatitis develops in approximately 75% of HCV recipients in the first six months following orthotopic liver transplantation (OLT). By the fifth postoperative year, over 80% of HCV-infected liver transplant recipients will develop histologic evidence of chronic allograft injury secondary to hepatitis C, with up to 30% developing cirrhosis. While the choice of calcineurin inhibitor has not been clearly shown to affect histologic recurrence of hepatitis C or the frequency of rejection in HCV-infected recipients, cumulative exposure to corticosteroids is associated with increased mortality, higher levels of HCV viremia and more severe histologic recurrence. Unfortunately, treatment of chronic HCV in liver transplant recipients is suboptimal. Combination therapy with interferon (pegylated and nonpegylated forms) plus ribavirin appears to provide maximum benefits. Drug therapy is usually administered for recurrent disease. No prophylactic therapy is available. Preemptive regimens offer no distinctive advantages over treatments initiated for recurrent disease. Overall, treatment is poorly tolerated, with frequent need for dose reductions, especially for cytopenias, and drug discontinuation in up to 50% of patients. Optimizing drug doses is important in maximizing sustained virologic response rates. The achieved SVR is between 33% and 42% in randomized studies treating patients with histologic recurrence and 0% to 33% when used in a preemptive protocol. The potential factors that influence this low SVR rate are: 1) high percentage of patients with genotype 1 virus; 2) high viral load at the start of treatment; 3) high percentage of prior non-responders to therapy; 4) side effects that often make the use of standard doses and duration of treatment difficult; 5) the use or not of growth factors; and 6) the effect of immunosuppression. In post-transplant patients with recurrent HCV disease, combination Peg alfa-2b or alfa-2a in standard dose and ribavirin (800-1200 mg either ab initio or as an increasing dose) regimen for 48 weeks was significantly better than no therapy, but not than any other therapy." @default.
- W2412530943 created "2016-06-24" @default.
- W2412530943 creator A5025651819 @default.
- W2412530943 creator A5029452776 @default.
- W2412530943 creator A5035932638 @default.
- W2412530943 creator A5076575674 @default.
- W2412530943 date "2009-12-01" @default.
- W2412530943 modified "2023-09-28" @default.
- W2412530943 title "[Treatment of recurrent hepatitis C infection after liver transplantation]." @default.
- W2412530943 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20198907" @default.
- W2412530943 hasPublicationYear "2009" @default.
- W2412530943 type Work @default.
- W2412530943 sameAs 2412530943 @default.
- W2412530943 citedByCount "0" @default.
- W2412530943 crossrefType "journal-article" @default.
- W2412530943 hasAuthorship W2412530943A5025651819 @default.
- W2412530943 hasAuthorship W2412530943A5029452776 @default.
- W2412530943 hasAuthorship W2412530943A5035932638 @default.
- W2412530943 hasAuthorship W2412530943A5076575674 @default.
- W2412530943 hasConcept C126322002 @default.
- W2412530943 hasConcept C203014093 @default.
- W2412530943 hasConcept C2522874641 @default.
- W2412530943 hasConcept C2776029263 @default.
- W2412530943 hasConcept C2776185481 @default.
- W2412530943 hasConcept C2776408679 @default.
- W2412530943 hasConcept C2776455275 @default.
- W2412530943 hasConcept C2776461080 @default.
- W2412530943 hasConcept C2777075537 @default.
- W2412530943 hasConcept C2777214474 @default.
- W2412530943 hasConcept C2778715236 @default.
- W2412530943 hasConcept C2779609443 @default.
- W2412530943 hasConcept C2780040827 @default.
- W2412530943 hasConcept C2911091166 @default.
- W2412530943 hasConcept C71924100 @default.
- W2412530943 hasConcept C90924648 @default.
- W2412530943 hasConceptScore W2412530943C126322002 @default.
- W2412530943 hasConceptScore W2412530943C203014093 @default.
- W2412530943 hasConceptScore W2412530943C2522874641 @default.
- W2412530943 hasConceptScore W2412530943C2776029263 @default.
- W2412530943 hasConceptScore W2412530943C2776185481 @default.
- W2412530943 hasConceptScore W2412530943C2776408679 @default.
- W2412530943 hasConceptScore W2412530943C2776455275 @default.
- W2412530943 hasConceptScore W2412530943C2776461080 @default.
- W2412530943 hasConceptScore W2412530943C2777075537 @default.
- W2412530943 hasConceptScore W2412530943C2777214474 @default.
- W2412530943 hasConceptScore W2412530943C2778715236 @default.
- W2412530943 hasConceptScore W2412530943C2779609443 @default.
- W2412530943 hasConceptScore W2412530943C2780040827 @default.
- W2412530943 hasConceptScore W2412530943C2911091166 @default.
- W2412530943 hasConceptScore W2412530943C71924100 @default.
- W2412530943 hasConceptScore W2412530943C90924648 @default.
- W2412530943 hasIssue "5" @default.
- W2412530943 hasLocation W24125309431 @default.
- W2412530943 hasOpenAccess W2412530943 @default.
- W2412530943 hasPrimaryLocation W24125309431 @default.
- W2412530943 hasRelatedWork W1494175477 @default.
- W2412530943 hasRelatedWork W1964558720 @default.
- W2412530943 hasRelatedWork W1974533295 @default.
- W2412530943 hasRelatedWork W1979332731 @default.
- W2412530943 hasRelatedWork W1982412440 @default.
- W2412530943 hasRelatedWork W1988581874 @default.
- W2412530943 hasRelatedWork W1996287485 @default.
- W2412530943 hasRelatedWork W1997229470 @default.
- W2412530943 hasRelatedWork W2007628011 @default.
- W2412530943 hasRelatedWork W2018102323 @default.
- W2412530943 hasRelatedWork W2020952797 @default.
- W2412530943 hasRelatedWork W2053093847 @default.
- W2412530943 hasRelatedWork W2060621721 @default.
- W2412530943 hasRelatedWork W2075374652 @default.
- W2412530943 hasRelatedWork W2093431073 @default.
- W2412530943 hasRelatedWork W2106814694 @default.
- W2412530943 hasRelatedWork W2124882260 @default.
- W2412530943 hasRelatedWork W2415545946 @default.
- W2412530943 hasRelatedWork W2471457656 @default.
- W2412530943 hasRelatedWork W3022068027 @default.
- W2412530943 hasVolume "63" @default.
- W2412530943 isParatext "false" @default.
- W2412530943 isRetracted "false" @default.
- W2412530943 magId "2412530943" @default.
- W2412530943 workType "article" @default.